NIOX GroupCSSPF 77 Graham Number is $0.25 as of Dec. 2025, which is 93% below its 10-year median of 3.42. GuruFocus rates CSSPF with a GF Score™ of 77/100 and a GF Value™ of $1.14 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 398 Medical Devices & Instruments companies, NIOX Group ranks worse than 72.61% on this metric.
Graham Number is a figure that measures a stock's fundamental value by taking into account the company's earnings per share and book value per share. The Graham number is the upper bound of the price range that a defensive investor should pay for the stock. According to the theory, any stock price below the Graham number is considered undervalued, and thus worth investing in.
As of today (2026-06-30), the stock price of NIOX Group is $0.75. NIOX Group's graham number for the quarter that ended in Dec. 2025 was $0.25. Therefore, NIOX Group's Price to Graham Number ratio for today is 3.02.
The historical rank and industry rank for NIOX Group's Graham Number or its related term are showing as below:
CSSPF'
s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.3 Med: 3.42 Max: 5.25
Current: 3
During the past 13 years, the highest Price to Graham Number ratio of NIOX Group was 5.25. The lowest was 1.30. And the median was 3.42.
CSSPF's Price-to-Graham-Number is ranked worse than 72.61% of 398
companies
in the Medical Devices & Instruments industry
Industry Median: 1.77
vs CSSPF: 3.00
Graham Number is a combination of asset valuation and earnings power valuation. It is a very conservative way of valuing a stock.
NIOX Group (OTCPK:CSSPF) Graham Number Explanation
Ben Graham actually did not publish a formula like this. But he wrote in The Intelligent Investor (1948 version) regarding to the criteria for purchases:
Current price should not be more than 15 times average earnings of the past three years.
Current price should not be more than 1.5 times the book value last reported. However, a multiplier of earnings below 15 could justify a correspondingly higher multiplier of assets. As a rule of thumb we suggest that the product of the multiplier times the ratio of price to book value should not exceed 22.5. (This figure corresponds to 15 times earnings and 1.5 times book value. It would admit an issue selling at only 9 times earnings and 2.5 times asset value, etc.)
Unlike valuation methods such as DCF or Discounted Earnings, the Graham number does not take growth into the valuation. Unlike the valuation methods based on book value alone, it takes into account the earnings power. Therefore, the Graham Number is a combination of asset valuation and earnings power valuation.
In general, the Graham number is a very conservative way of valuing a stock. It cannot be applied to companies with negative book values.
NIOX Group's Price to Graham number Ratio for today is calculated as
Price to Graham number
=
Share Price (Today)
/
Graham number (Q: Dec. 2025 )
=
0.75
/
0.25
=
3.02
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Please keep these in mind:
1. Graham Number does not take growth into account. Therefore it underestimates the values of the companies that have good earnings growth. We feel that if the earnings per share grows more than 10% a year, Graham Number underestimates the value.
2. Graham Number punishes the companies that have temporarily low earnings. Therefore, an average of earnings makes more sense in the calculation of Graham Number.
3. Graham Numbers underestimates companies that are light with book.
NIOX Group Graham Number Related Terms
NIOX Group Graham Number Historical Data
* Premium members only.
The historical data trend for NIOX Group's Graham Number can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, NIOX Group's Price-to-Graham-Number, along with its competitors' market caps and Price-to-Graham-Number data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NIOX Group Price-to-Graham-Number vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, NIOX Group's Price-to-Graham-Number distribution charts can be found below:
* The bar in red indicates where NIOX Group's Price-to-Graham-Number falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NIOX Group (CSSPF) has a Graham Number of $0.25 as of Dec. 2025. The Graham Number values a company based on its per-share earnings and book value. View historical data on NIOX Group and its competitors. This is 93% below median its historical median of 3.42. Over the past decade, NIOX Group's Graham Number has ranged from 1.30 to 5.25. According to the industry distribution chart, NIOX Group ranks #289 out of 398 companies in the Medical Devices & Instruments industry, placing it in the top 72.6%.
Is NIOX Group's Graham Number too high?
NIOX Group's current Graham Number of $0.25 is 93% below median its 10-year median of 3.42. Over the past 10 years, this metric has ranged from a low of 1.30 to a high of 5.25. The Medical Devices & Instruments industry median Graham Number is 1.77. NIOX Group's value of $0.25 is 85.9% below this industry median. Based on the distribution chart, NIOX Group ranks #289 out of 398 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, NIOX Group has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does NIOX Group's Graham Number compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, NIOX Group ranks #289 out of 398 companies for Graham Number. This places NIOX Group in the lower half of its industry. The industry median Graham Number is 1.77. NIOX Group's value of $0.25 is 85.9% below this benchmark. Historically, NIOX Group's own Graham Number has ranged from 1.30 to 5.25 over the past decade. While the company's 10-year median is 3.42 vs. the industry median of 1.77, NIOX Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Graham Number for a Medical Devices & Instruments company?
The median Graham Number among Medical Devices & Instruments companies is 1.77, based on 398 companies in the industry. Companies in the top quartile (top 25%) have a Graham Number significantly above this median, while those in the bottom quartile fall well below. However, Graham Number should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NIOX Group's current Graham Number of $0.25 is 85.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Graham Number mean?
A high Graham Number can signal that a stock is expensive relative to its fundamentals. The Graham Number values a company based on its per-share earnings and book value. View historical data on NIOX Group and its competitors. For the Medical Devices & Instruments industry, the median Graham Number is 1.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NIOX Group's current Graham Number is $0.25, which is 93% below median its own 10-year median of 3.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NIOX Group stock overvalued right now?
Based on GuruFocus' analysis, NIOX Group (CSSPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $1.14, compared to a current price of $0.75 — trading 34.2% below its estimated fair value. The current Graham Number is $0.25, which is 93% below median its 10-year median of 3.42 and 85.9% below the Medical Devices & Instruments industry median of 1.77. NIOX Group's overall GF Score™ is 77/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Graham Number calculated?
Graham Number is calculated from a company's financial statements. For NIOX Group (CSSPF), the current Graham Number is $0.25 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NIOX Group (CSSPF) Overvalued in 2026?
Based on GuruFocus' analysis, NIOX Group stock appears to be undervalued.
The current stock price of $0.75 is trading 34.2% below its estimated GF Value™ of $1.14.
GuruFocus considers NIOX Group to be Significantly Undervalued.
Key valuation signals for CSSPF:
Graham Number: $0.25 (93% below median its 10-year median of 3.42)
GF Value™: $1.14 vs. price of $0.75 (34.2% below fair value)
Industry Position: 85.9% below the Medical Devices & Instruments median (#289 of 398)
No single metric tells the full story. See the CSSPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NIOX Group PLC is engaged in improving the diagnosis, monitoring and management of both asthma and COPD by providing greater patient access to FeNO testing. The company is engaged in the design, development, and commercialization of medical devices for the measurement of FeNO, a precise biomarker for type 2 inflammation which is present in asthma and COPD. Its device, NIOX VERO, is increasingly recognised by healthcare professionals as an important tool to improve the diagnosis, monitoring and management of asthma and COPD. It operates in single segment of NIOX relates to the portfolio of products used to improve asthma diagnosis, monitoring and management by measuring fractional exhaled nitric oxide (FeNO).
77GF Score
Get the complete analysis for CSSPF
Graham Number is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSSPF has been successfully added to your 
